Nifedipine |
Adalat; Procardia |
Article: Nifedipine
![]() | |
| Nifedipine | |
| Systematic (IUPAC) name | |
| dimethyl2,6-dimethyl-4-(2-nitrophenyl)- 1,4-dihydropyridine-3,5-dicarboxylate | |
| Identifiers | |
| CAS number | 21829-25-4 |
| ATC code | C08CA05 |
| PubChem | 4485 |
| DrugBank | APRD00590 |
| Chemical data | |
| Formula | C17H18N2O6 |
| Mol. weight | 346.335 g/mol |
| Physical data | |
| Melt. point | 6°C (43°F) |
| Pharmacokinetic data | |
| Bioavailability | 45-56% |
| Protein binding | 92-98% |
| Metabolism | Gastrointestinal, Hepatic |
| Half life | 2 hours |
| Excretion | Renal: >50%, Biliary: 5-15% |
| Therapeutic considerations | |
| Pregnancy cat. | C: (USA) |
| Legal status | |
| Routes | Oral |
Nifedipine (brand name Adalat and Procardia) is a dihydropyridine calcium channel blocker. Its main uses are in angina pectoris (especially Prinzmetal's angina) and hypertension, although a large number of other uses have recently been found for this agent, such as Raynaud's phenomenon, premature labor, and painful spasms of the esophagus in cancer patients.
Nifedipine lowers the blood pressure rapidly, and patients are commonly warned they may feel dizzy or faint after taking the first few doses. Tachycardia (fast heart rate) may occur as a reaction. These problems are much less frequent in the sustain-release preparations of nifedipine (such as Adalat OROS).

Not Signed In - 


